

AMENDMENTS TO THE CLAIMS

1.-5. (canceled)

6. (currently amended) The compound according to claim 2 wherein n is 1, 2  
or 3

(+/-)-3-(trans-3,4-Dimethyl-1-phenethyl-piperidin-4-yl)-benzamide;  
(+/-)-3-(1-[2-(4-Methoxy-phenyl)-ethyl]-trans-3,4-dimethyl-piperidin-4-yl)-  
benzamide;  
(+/-)-3-[1-[2-(2-Methoxy-phenyl)-ethyl]-trans-3,4-dimethyl-piperidin-4-yl]-  
benzamide;  
(+/-)-3-[1-[2-(3-Methoxy-phenyl)-ethyl]-trans-3,4-dimethyl-piperidin-4-yl]-  
benzamide;  
(+/-)-3-[trans-3,4-Dimethyl-1-[2-(3-trifluoromethyl-phenyl)-ethyl]-piperidin-4-yl]-  
benzamide;  
(+/-)-3-[1-[2-(4-Cyano-phenyl)-ethyl]-trans-3,4-dimethyl-piperidin-4-yl]-benzamide;  
(+/-)-3-[1-[2-(3-Bromo-phenyl)-ethyl]-trans-3,4-dimethyl-piperidin-4-yl]-benzamide;  
(+/-)-3-[1-[2-(4-Chloro-phenyl)-ethyl]-trans-3,4-dimethyl-piperidin-4-yl]-benzamide;  
(+/-)-3-[1-[2-(3-Chloro-phenyl)-ethyl]-trans-3,4-dimethyl-piperidin-4-yl]-benzamide;  
(+/-)-3-[1-[2-(3-Cyano-phenyl)-ethyl]-trans-3,4-dimethyl-piperidin-4-yl]-benzamide;  
(+/-)-3-[1-[2-(2,6-Dichloro-phenyl)-ethyl]-trans-3,4-dimethyl-piperidin-4-yl]-  
benzamide; or  
(+/-)-3-[1-[2-Hydroxy-2-phenyl-ethyl]-trans-3,4-dimethyl-piperidin-4-yl]-benzamide;  
or a pharmaceutically acceptable salt thereof.

7. (currently amended) The compound according to claim 2 wherein R<sup>4</sup> is OH,  
CH<sub>2</sub>OH, NH<sub>2</sub>, NHCOCH<sub>3</sub> or CN (+/-)-3-[1-[2-(2-Methoxy-phenyl)-ethyl]-trans-3,4-dimethyl-  
piperidin-4-yl]-benzamide or a pharmaceutically acceptable salt thereof.

8.-19. (canceled)

20. (currently amended) A pharmaceutical composition comprising an effective amount of a compound according to claim 6 or 7 any of claims 1-7 and 9-10 in combination with a pharmaceutically acceptable carrier, excipient or additive.

21. (canceled)

22. (currently amended) A method of treating in a mammal, in need thereof, a disease state, disorder or condition selected from the group consisting of irritable bowel syndrome, constipation, nausea, vomiting, pruritic dermatoses, psoriasis, eczema; an insect bite; an eating disorder, depression, anxiety, schizophrenia; drug addiction, an opioid overdose, sexual dysfunction, stroke, head trauma, traumatic brain injury, spinal damage, Parkinson's disease, Alzheimer's disease, age related cognitive decline and Attention Deficit and Hyperactivity Disorder which method comprises administering to said mammal an therapeutically effective amount of a compound according to claim 6 or 7 any of claims 1-7 and 9-10 effective in treating said disease state, disorder or condition.

23.-29. (canceled)